ERBB2 and breast cancer: MTOR signaling is associated with tolerance to HER2 therapeutic mechanisms in BC, the case in point is the dual epidermal growth factor receptors HER1 and HER2, the antibody-based agent trastuzumab, and the inhibitor lapatinib (Luey and May, 2016).